Population pharmacokinetics of single-dose intravenous paracetamol in children

B S Mohammed1, T Engelhardt, G A Cameron

  • 1Division of Applied Health Sciences, University of Aberdeen, Royal Aberdeen Children's Hospital, Aberdeen, UK.

Insights

Intravenous paracetamol pharmacokinetics in children aged 1.8-15 years are primarily influenced by body weight, not age. Allometric scaling of clearance and distribution volumes confirms weight as a key factor in pediatric dosing.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Development

Background:

  • Intravenous (i.v.) paracetamol (Perfalgan) is a new formulation for pediatric use.
  • Understanding its pharmacokinetic profile in children is crucial for safe and effective dosing.

Purpose of the Study:

  • To determine the pharmacokinetics (PK) of i.v. paracetamol in children up to 15 years of age.
  • To identify factors influencing paracetamol's absorption, distribution, metabolism, and excretion in this population.

Main Methods:

  • Population pharmacokinetic analysis using non-linear mixed-effect modeling (NONMEM).
  • Measurement of paracetamol concentrations via validated high-performance liquid chromatography (HPLC) with ultraviolet detection.
  • Blood samples collected at multiple time points post-administration of weight-dependent i.v. paracetamol doses.

Main Results:

  • Data from 33 children (1.8-15 years) were analyzed.
  • A two-compartment model best described the data, with body weight as the only significant covariate.
  • Population models for clearance (CL) and volume of distribution (V(1), V(2)) were established, incorporating allometric scaling based on body weight (WT).

Conclusions:

  • Pediatric i.v. paracetamol pharmacokinetics are significantly influenced by total body weight, not directly by age.
  • Allometric size scaling effectively predicted clearance and distribution volumes, supporting weight-based dosing strategies.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...